# Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

> **NCT00287859** · PHASE1 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 5 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00287859
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-08
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Withdrawn due to low accrual
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287859, "Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00287859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*